Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars
Home / News / BioBlast™ Archive

BIOSIMILARS UPDATES

Our BioBlast™ Archive

Explore biologics and biosimilars news updates (BioBlast®) at Pearce IP

BioBlast w/e 17 Nov 23

16 NOV 2023 | US | Approval Alert: AZ’s Truqap® (capivasertib) plus Faslodex® FDA Approved to Treat Advanced HR-positive Breast Cancer AstraZeneca (AZ) announced the FDA approved its Truqap® (capivasertib) in combination with Faslodex...

BioBlast w/e 10 Nov 23

10 NOV 2023 | EU | CHMP Positive Opinion for 8mg Eylea® (Aflibercept) Bayer announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of 8mg Eylea® (aflibercept) intravitreal injection for the...

BioBlast w/e 03 Nov 23

01 NOV 2023 | EU | Fresenius Kabi’s Launches First EU Tocilizumab Biosimilar Fresenius Kabi announced it has launched Tyenne®, the first EC-approved biosimilar to Roche’s Actemra®/RoActemra® in the EU.  Tyenne® was approved by the EC on 19...

BioBlast w/e 27 Oct 23

27 OCT 2023 | US | Sanofi to Spin-Off Consumer Business and Focus on Biopharma by End Q4 2023 Sanofi announced that it will separate its Consumer Healthcare Business as soon as the end of Q4 2024, creating a publicly listed company headquartered...

BioBlast w/e 23 Oct 23

23 OCT 2023 | US | Approval Alert: FDA Approves Celltrion’s Zymfentra® (infliximab-dyyb), Biosimilar to Janssen’s Remicade®, and the First Approved SC Infliximab Celltrion announced that the FDA has approved its subcutaneous formulation of...

BioBlast w/e 15 Oct 23

15 OCT 2023 | Samsung Bioepis Reveals SB16 (denosumab) Study Results at ASBMR Samsung Bioepis presented new data on its SB16 (denosumab, biosimilar to Amgen’s Prolia®) at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual...

BioBlast w/e 07 Oct 23

07 OCT 2023 | Samsung Bioepis Presents Switching Study Results for SB15, Biosimilar to Regeneron’s Eylea® (aflibercept) Samsung Bioepis announced its Phase III switching study results for SB15, biosimilar to Regeneron’s Eylea® (aflibercept), at...

BioBlast w/e 02 Oct 23

02 OCT 2023 | Nobel Prize Awarded to Katalin Karikó and Drew Weissman for Their Work Which Supported the mRNA COVID-19 Vaccine The Nobel Assembly at Karolinska Institutet awarded the 2023 Nobel Prize in Physiology or Medicine jointly to Katalin...

Meet our BioBlast™ authors

Naomi Pearce & Emily Bristow

Naomi Pearce & Emily Bristow

Naomi and Emily author the weekly BioBlast™ update, ensuring that everyone is kept up to date with the latest happenings within the biosimilars industry.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.